Telios Pharmaceuticals Inc. has filed an investigational newdrug (IND) application with the FDA for its platelet aggregationinhibitor, TP-9201.

The compound is a synthetic cyclic peptide containing the celladhesion sequence arginine-glycine-aspartic acid (RGD). It'sdesigned to inhibit platelet aggregation by specifically blockingfibrinogen receptors on platelets (the GPIIb/IIIa receptors).

Studies of TP-9201 in animal models indicate that thecompound is fast-acting, reversible, non-immunogenic andinhibits blood clotting without increasing bleeding time. Telios(NASDAQ:TLIO) of San Diego intends to study TP-9201's abilityto treat acute conditions such as myocardial infarction, unstableangina and stroke. The compound could also prove useful inpreventing abrupt closure after angioplasty or vascularsurgery. -- Jennifer Van Brunt

(c) 1997 American Health Consultants. All rights reserved.